Modulating the host immune response to fight against COVID-19: Where are we in 2021?

Hertanto, Decsa Medika; Sutanto, Henry; Wiratama, Bayu Satria; Wungu, Citrawati Dyah Kencono

Hertanto, Decsa Medika; Sutanto, Henry; Wiratama, Bayu Satria; Wungu, Citrawati Dyah Kencono.

Hertanto DM; Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya, Indonesia.
Sutanto H; Department of Internal Medicine, Soetomo General Hospital, Surabaya, Indonesia.
Wiratama BS; Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands.
Wungu CDK; Department of Epidemiology, Biostatistics, and Population Health, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.

Virulence ; 12(1): 1732-1736, 2021 12.

Article in English | MEDLINE | ID: covidwho-1294647

Subject(s)

COVID-19 Drug Treatment; COVID-19/immunology; SARS-CoV-2/immunology; Antiviral Agents/therapeutic use; COVID-19/prevention & control; Cytokine Release Syndrome/drug therapy; Drug Repositioning; Host-Pathogen Interactions/drug effects; Host-Pathogen Interactions/immunology; Humans; Immunity; Immunomodulation; SARS-CoV-2/drug effects

Keywords

COVID-19; SARS-CoV-2; coronavirus; drug repurposing; immune system; immunology; immunomodulation; pharmacotherapy

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / COVID-19 Drug Treatment Limits: Humans Language: English Journal: Virulence Year: 2021 Document Type: Article Affiliation country: 21505594.2021.1943275

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google